Navigation Links
MonoSol Rx Granted U.S. Article of Manufacture Patent
Date:4/2/2009

Patent Addresses Use of Thin Film to Deliver Drugs and Vitamins via Pacifier or Porous Nipple

WARREN, N.J., April 2 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that it has been granted U.S. Patent No. 7,500,984 from the United States Patent and Trademark Office (USPTO). The patent relates to the delivery of an active ingredient, such as drugs and/or vitamins, contained in a thin film that is attached or placed inside of a pacifier or porous nipple member, such as the tip of a baby bottle.

A. Mark Schobel, President and Chief Executive Officer of MonoSol Rx, stated, "An infant's natural propensity to suckle makes pacifiers and bottle nipples useful devices for administering medication and vitamins. Affixing a quick dissolving thin film into the porous nipple of a bottle or pacifier ensures that the active ingredient is immediately released into the oral cavity upon contact with saliva or liquid from the bottle. This particular use of thin film allows for a more rapid and uniform delivery of the active compound and increased compliance from caregivers who struggle with administering drugs and vitamins to their infants and small children. Having secured the patent, we are currently looking at potential business development opportunities for this novel thin film drug delivery approach."

According to the provisions of the patent, the process entails securing a thin film to the inside rim of a pacifier or nipple. The liquid from the bottle or reservoir triggers the release of the active ingredient without requiring the patient to finish the entire bottle for a complete dose. Delivery of a complete and accurate dose is confirmed as the thin film dissolves and disappears from the inside surface of the pacifier or porous nipple. The technology is designed particularly for infants and patients such as the elderly, and those who have had surgery or other illnesses which prevent the ordinary dispensing of medication. The device may be used for veterinary applications as well.

Schobel continued, "Our newest U.S. patent further strengthens our leadership and intellectual property position in thin film drug delivery and development, particularly in difficult-to-treat patient populations. Our robust and growing IP portfolio enables MonoSol Rx to have leadership capabilities in the critical areas of drug taste-masking, film composition, manufacturing, packaging and novel therapeutic film applications."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver drugs in quick dissolving films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in thin film drug delivery is supported by strong intellectual property, a portfolio of commercialized over-the-counter (OTC) drug products, and a development pipeline of prescription formulations based on PharmFilm(R) technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that fund prescription product development programs that will generate long-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing. For existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).

    Contact:
    MonoSol Rx
    Keith Kendall
    Chief Financial Officer
    (732) 564-5000 

    The Ruth Group
    Jason Rando (media)
    (646) 536-7025
    jrando@theruthgroup.com

    Stephanie Carrington / Sara Ephraim (investors)
    (646) 536-7017 / 7004
    scarrington@theruthgroup.com
    sephraim@theruthgroup.com


'/>"/>
SOURCE MonoSol Rx
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MonoSol Rx Enters Agreement with Hikma Pharmaceuticals PLC for Thin Film Pharmaceutical Products in the Middle East
2. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
3. MonoSol Rx to Present at the 20th Annual Piper Jaffray Health Care Conference
4. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
5. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
6. MonoSol Rx Names Vincent Viviani Senior Vice President, Manufacturing and Operations
7. MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
8. Microfluidic Systems (MFSI) is Granted a Microfluidic Cartridge Patent for DNA Separation
9. Skinvisible Patent Granted for Japan
10. Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene
11. The 2009 Damon Runyon-Rachleff Innovation Award Granted for Pioneering Ideas for Early Detection of Ovarian and Lung Cancers, Bone Marrow Transplant Safety, and Discovery of New Genetic Markers for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
Breaking Medicine Technology: